BeyondSpring Inc.

BeyondSpring Inc. is a clinical-stage biopharmaceutical company focused on developing cancer therapies for patients with high unmet medical needs. Its lead asset is Plinabulin, a first-in-class small molecule being studied across multiple oncology indications as a potential "pipeline in a drug." The company also has additional small-molecule immune agents in development, but it has not yet commercialized any approved product. BeyondSpring’s business model is centered on advancing clinical programs, protecting intellectual property, and securing partnerships or financing to support development and future commercialization.

1.54

— BeyondSpring Inc.
	%
Plinabulin development	70% Clinical development of Plinabulin across multiple cancer indications as a potential direct anti-cancer therapy.
Partnered commercialization rights	20% Regional licensing and collaboration rights for Plinabulin and related programs, especially in Greater China.
Pipeline research and discovery	10% Preclinical and early-stage work on additional small molecule immune agents and new product candidates.

BeyondSpring does not currently sell approved products directly to end customers, so its near-term counterparties are...

Pharmaceutical licensing partnersprimary
Partners such as Hengrui that may commercialize Plinabulin in defined territories and share development or commercialization economics.
Research and clinical collaboratorsprimary
CROs, hospitals, and institutions that support preclinical work and clinical trials needed to advance the pipeline.
Future oncology treatment providersemerging
Hospitals, physicians, and healthcare systems that would buy or prescribe approved oncology products if Plinabulin reaches market.
Government reimbursement stakeholderssecondary
Chinese regulatory and reimbursement bodies that influence pricing, approval, and patient access for Plinabulin.

BeyondSpring is headquartered in the United States, but a meaningful part of its development and partnering strategy is...

•United States is the corporate base and primary reporting jurisdiction
•Greater China is strategically important for Plinabulin partnering and approval
•Wanchunbulin operates under PRC local grant conditions and restrictions
•Commercialization in China depends on pricing and reimbursement decisions
•Future ex-U.S. monetization may rely on global licensing or co-development partners

BeyondSpring’s strategy is to advance Plinabulin through clinical development and regulatory approval while preserving...

Clinical and regulatory advancement of Plinabulinshort-term

Approval is the main path to product revenue and to unlocking partnering value.

China commercialization and reimbursement strategymedium-term

China is the clearest near-term partnering market and may provide the first commercial pathway.

Capital and partnership flexibilityshort-term

The company needs external funding and may monetize through licensing, equity, or asset transactions.

BeyondSpring is exposed to the core risks of a clinical-stage biotech: clinical failure, regulatory delay, and the...

critical

Clinical development failure

Plinabulin and other pipeline assets must succeed in trials before any product revenue can be generated.

Scope: Lead asset Plinabulin and broader oncology pipeline
Materiality: high

high

Financing and dilution risk

The company expects to need substantial additional capital and may rely on equity, debt, or asset sales.

Scope: Corporate liquidity and ongoing R&D funding
Materiality: high

high

Partner dependence

Commercialization strategy depends on collaboration arrangements that may be hard to secure on favorable terms.

Scope: China and ex-China licensing/commercialization
Materiality: high

high

China regulatory and reimbursement risk

Approval, pricing negotiations, and insurance inclusion in China will determine access and economics.

Scope: Greater China commercialization
Materiality: high

medium

Intellectual property protection

The company’s value depends heavily on patent and trade secret protection for Plinabulin and related programs.

Scope: Pipeline value and partnering leverage
Materiality: medium

Deferred revenue recognition for Hengrui upfront payment

Can materially shift revenue into future periods and distort near-term comparability

Discontinued operations accounting

Can make operating losses and revenue trends appear different across periods

R&D expense estimation

Quarterly operating loss and cash burn can fluctuate materially

Collaboration revenue and milestone timing

Revenue may be highly uneven and dependent on contract events

BeyondSpring Inc.

Clinical development failure

Financing and dilution risk

Partner dependence

China regulatory and reimbursement risk

Intellectual property protection

Ventyx Biosciences, Inc.

PLIANT THERAPEUTICS, INC.

NextCure, Inc.

Moleculin Biotech, Inc.

LeonaBio, Inc.

Replimune Group, Inc.